This study is looking at whether adding an investigational medicine called XEN1101 to your current treatment may help reduce generalized tonic-clonic seizures.
Taking part is your choice. You can leave the study at any time.
Condition
Epilepsy
Who it's for
12 years and older
Visits
Multiple visits over approximately 7 months
Time commitment
12 weeks
Study format
In-person study with at-home seizure tracking
Study treatment
Provided, free to you
Compensation
Travel support or reimbursement may be available, depending on your study site.
Your privacy
Kept private and secure
Eligibility
If you have been diagnosed with this condition, you may be eligible to take part. Here is a simple guide to who can join.
These are general guidelines. The study team confirms who can join after a short, friendly check.
In plain words
This study is evaluating whether adding XEN1101 to your current epilepsy medications can help reduce primary generalized tonic-clonic seizures in people whose seizures are not fully controlled. There are no surgeries or implants involved. The study medication is a once-daily capsule taken by mouth, along with routine health checks, seizure tracking, and scheduled clinic visits. While benefits cannot be guaranteed, participating may provide access to a potential new treatment option and help researchers improve care for others living with generalized epilepsy.
The challenge today
Some people with generalized epilepsy continue to experience tonic-clonic seizures even while taking anti-seizure medications. New treatment options are needed.
What researchers hope to learn
Researchers want to find out whether adding XEN1101 to existing treatment can safely reduce the number of generalized tonic-clonic seizures.
How this study treatment may help
If XEN1101 is effective, it may help some people experience fewer seizures and improve their quality of life. However, benefits cannot be guaranteed.
The study team will review your medical history, current medications, and seizure history. You'll complete health checks and record your seizures in a diary.
You will continue taking your regular anti-seizure medications and be randomly assigned to receive either XEN1101 or a placebo capsule once daily with your evening meal.
You may choose to join a separate long-term extension study to continue receiving XEN1101. If not, you'll attend follow-up visits.
1.Learn about the study
Read this page at your own pace. There is no pressure to decide anything today.
2.Answer a few quick questions
A short eligibility questionnaire takes about 5 to 10 minutes.
3.Connect with the study team
A coordinator answers your questions and explains next steps.
4.Review the consent information
You will get clear, written details before you agree to anything.
5.Screening and medical review
Simple checks confirm whether the study is a good fit for you.
6.Confirm you can join
Not eligible? We may help you find other studies that fit you better.
7.Join the study
You start only when you feel ready and have given your consent.
8.Attend visits and track how you feel
The team supports you through every appointment and check-in.
9.Complete follow-up activities
A few final check-ins help the team learn from your experience.
10.Finish the study
You are free to ask questions about your results and what comes next.
Visit the study team on the scheduled dates so they can check how you are doing.
Follow the simple instructions the team gives you for the study treatment.
Note how you feel so the team understands your experience.
Answer a few easy questions about your health and well-being.
The study team will walk you through every possible before you decide. You will have time to ask questions.
Travel support or reimbursement may be available, depending on your study site.
No. You do not need insurance to take part, and study-related care is provided at no cost to you.
Often yes, but it depends on the study. Share your full medication list with the study team and they will guide you.
Yes. Taking part is your choice, and you can stop at any time for any reason, without affecting your regular care.
You can call or email the study team any time. There is no such thing as a question that is too small.
Yes. Your information is kept private and secure, and only approved people can see your study data.
Tap any word to see a plain-language meaning.
Family members and caregivers are welcome to help you decide. You do not have to do this alone.
Prefer we reach out? Request a callback at a time that works for you.
Xenon Pharmaceuticals
Phase III, Randomized, Double-Blind, Placebo-Controlled Study evaluating the safety, tolerability, and efficacy of XEN1101 as adjunctive therapy in focal-onset seizures.
Epilepsy eligibility
Select any one
